Curious whether AstraZeneca’s current stock price accurately represents its actual value, or if the market is overreacting? This article aims to clarify the assessment of its valuation.
Currently, AstraZeneca’s share price stands at £152.52, with returns of 12.1% over the past 30 days, 12.2% year-to-date, and 30.4% over the last year. These significant fluctuations may alter investors’ perceptions of its potential and associated risks.
Current Stock Performance
The latest media reports have highlighted AstraZeneca’s product development, collaborations, and regulatory changes, all of which shape investor perceptions regarding future cash flows and the company’s resilience. These factors can affect whether the current share price appears inflated or justified when assessed against the fundamental metrics.
AstraZeneca presently holds a valuation score of , indicating that it is considered undervalued based on half of the criteria we apply. We will now analyze how this score is derived through various valuation techniques, concluding with a comprehensive approach that integrates all these elements.
Ad placement
Valuation Assessment Factors
Method 1: Discounted Cash Flow (DCF) Evaluation for AstraZeneca
A Discounted Cash Flow (DCF) model evaluates the projected cash that AstraZeneca may produce in the future and adjusts those figures to reflect their current value. The concept is straightforward: it seeks to determine the present value of all anticipated cash flows.
AstraZeneca’s most recent twelve-month free cash flow stands at approximately US$9.5 billion. Based on analyst estimates and subsequent projections, it is anticipated that free cash flow could rise to around US$20.3 billion by 2030. Annual figures from 2026 to 2035 are discounted back to present value utilizing a two-stage free cash flow to equity methodology. Where possible, analyst predictions are incorporated, and later years are extrapolated by Simply Wall St.
Market Reactions and Trends
By consolidating the cash flows, the DCF model estimates an intrinsic value of US$232.73 for each share. In contrast to the current share price of £152.52, this suggests that the stock appears to be approximately 34.5% undervalued according to this analysis.
Outcome: UNDERPRICED
Our Discounted Cash Flow (DCF) evaluation indicates that AstraZeneca is priced 34.5% lower than its true value. Monitor this in your portfolio, or explore further options.
Future Outlook for Investors
AstraZeneca’s Discounted Cash Flow analysis as of March 2026
Method 2: AstraZeneca Share Price Compared to Earnings
The P/E ratio serves as an effective method for assessing the value of profitable firms, as it connects the price you pay for each share to the earnings that support that share. It provides a quick overview of how many years of current earnings investors are prepared to pay for.
The definition of a “normal” P/E ratio varies based on investor expectations for growth and their perception of the risk associated with those earnings. Typically, quicker and more dependable earnings can warrant a higher P/E, whereas slower or less predictable earnings are more likely to lead to a lower P/E.
AstraZeneca’s current share price reflects a P/E ratio of 31.0x, in contrast to the average of approximately 22.2x within the Pharmaceuticals sector and a peer average of 12.7x. The Fair Ratio assigned by Simply Wall St for AstraZeneca stands at 39.1x. This Fair Ratio represents a proprietary assessment of what AstraZeneca’s P/E might justifiably be, taking into account elements like its earnings growth trajectory, industry standards, profit margins, market capitalization, and significant risks.
The Fair Ratio offers deeper insights compared to a straightforward peer or industry comparison, as it seeks to account for AstraZeneca’s unique blend of growth, risk, and profitability instead of presuming that all companies should be valued at the same multiple.
Evaluating the Fair Ratio of 39.1x against the existing P/E of 31.0x indicates that the shares appear to be undervalued based on this criterion.
AstraZeneca Share Price: 1-Year Stock Price Graph
This article from Simply Wall St is intended for general informational purposes. We offer insights based on historical data and analyst predictions, employing an impartial approach, and our content should not be interpreted as financial advice. It is not a suggestion to purchase or sell any shares, nor does it consider your personal goals or financial circumstances. Our objective is to provide analysis focused on long-term perspectives, grounded in fundamental data. Please be aware that our evaluations may not incorporate the most recent price-sensitive announcements from companies or qualitative information. Simply Wall St does not hold any shares in the stocks discussed.
Introducing: Consolidate All Your Stock Investments in a Single Location. We have developed the ultimate companion for stock traders, and it’s completely free. • Link an unlimited number of portfolios and view your total in a single currency.
• Receive notifications about new Warning Signs or Risks through email or mobile alerts
• Monitor the True Worth of your shares
Experience a Free Demo Portfolio Today
If you have thoughts about this article or concerns regarding the content, please reach out to us directly. Alternatively, you can email us at [email protected].
You may also like
